Evaluation of the skin carcinogenicity of the TRPV1 antagonist motugivatrep (SJP-0132) using an ultra-short-term two-stage skin carcinogenesis assay in Tg-rasH2 mice
Yoshinori Yamagiwa, Mayumi Kawabe, Yuko Doi, Shingo Nemoto, Ikuyo Atsumi · 2026
Read Evaluation of the skin carcinogenicity of the TRPV1 antagonist motugivatrep (SJP-0132) using an ultra-short-term two-stage skin carcinogenesis assay in Tg-rasH2 mice by Yoshinori Yamagiwa, Mayumi Kawabe, Yuko Doi, Shingo Nemoto, Ikuyo Atsumi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13342311.txt.
Description
Yoshinori Yamagiwa and co-authors test whether an eye drug promotes skin tumors in mice in this 2026 study. The drug blocks a sensing channel and is being developed for dry eye disease. Whether blockers of that channel affect skin cancer growth is disputed, so a safety test was needed.
Genetically altered mice first got a single skin dose of a tumor-starting chemical. The drug was then put on the skin daily for seven weeks at three doses, while a control group got a known tumor promoter weekly. No skin tumors or early lesions appeared in any drug-treated animal. The promoter group grew many tumors, which confirmed the test worked. The drug showed no tumor promotion in this model.
Catalog record
| CREATOR | Yoshinori Yamagiwa, Mayumi Kawabe, Yuko Doi, Shingo Nemoto, Ikuyo Atsumi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |